PaxMedica Releases 2022 Shareholder Letter

February 15, 2023

https://www.globenewswire.com/news-release/2023/02/15/2608576/0/en/PaxMedica-Releases-2022-Shareholder-Letter.html

Company Anticipates Multiple Milestones in Next 12-24 Months

TARRYTOWN, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – PaxMedica, Inc. (Nasdaq:PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today released a 2022 shareholder letter discussing its recent accomplishments and upcoming milestones.

Read more at globenewswire.com

Related news for (PXMD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.